Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome
about
The involvement of cholesterol in sepsis and tolerance to lipopolysaccharide highlighted by the transcriptome analysis of zebrafish (Danio rerio)The role and utility of faecal markers in inflammatory bowel disease.Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel diseaseBiomarkers in inflammatory bowel disease: current practices and recent advances.The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.S100A12: a noninvasive marker of inflammation in inflammatory bowel disease.Biomarkers in management of inflammatory bowel disease.Update on clinical and research application of fecal biomarkers for gastrointestinal diseases.Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases.Lessons to be learned from serum biomarkers in psoriasis and IBD - the potential role in SpA.The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Study.The role of S100A12 as a systemic marker of inflammation.Potential effects of calcium binding protein S100A12 on severity evaluation and curative effect of severe acute pancreatitis.Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets
P2860
Q28468675-C6A27200-2740-4F1C-83B5-C495BA2DEA1BQ34456258-4F7CF784-FE01-47CA-B093-F81BAEEE3F9AQ35244325-73064373-FF13-417E-8028-B9E52CA7AED6Q35840853-1EC190CE-806A-4F36-A48D-418480D18043Q37870433-679E9FA1-261A-42B9-AB8C-F467BD0A6E1EQ38059248-396DAFC7-A310-4A36-B00C-C9D767994138Q38215501-5B6A9AB9-8424-436A-ABF2-8063FF966399Q38755379-3C776542-DE20-4E71-9653-82AFEEF1DE6DQ38756562-BC99E329-A235-4B30-86EC-5FEA9CF12FF1Q38881849-63CFC4E5-92FF-4E5F-8FF1-E02731C67033Q38972679-8A1931D0-52D6-4890-B751-BF863DA567D3Q41253670-B5BA71BC-681F-42F2-BE92-CAFC362B321BQ42234262-585AEB3D-3446-4870-9CAD-F5456191B1CEQ51110150-8ADCC4CF-33A5-4264-B0FD-63C923C1EA72Q58699651-45A323E1-F9A8-4C9E-9E75-C80383BFD81F
P2860
Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Moderate performance of serum ...... from irritable bowel syndrome
@ast
Moderate performance of serum ...... from irritable bowel syndrome
@en
type
label
Moderate performance of serum ...... from irritable bowel syndrome
@ast
Moderate performance of serum ...... from irritable bowel syndrome
@en
prefLabel
Moderate performance of serum ...... from irritable bowel syndrome
@ast
Moderate performance of serum ...... from irritable bowel syndrome
@en
P2093
P2860
P356
P1433
P1476
Moderate performance of serum ...... from irritable bowel syndrome
@en
P2093
Anastasia Kapsoritaki
Anastassios C Manolakis
Andreas N Kapsoritakis
Chara Tzavara
Panagiotis Georgoulias
Spyros P Potamianos
Varvara Valotassiou
P2860
P2888
P356
10.1186/1471-230X-10-118
P577
2010-10-14T00:00:00Z
P6179
1045891880